Myriad Genetics, Inc. Q2 2026 Financial Report – Investor Brief
Key Highlights
- Quarterly Report Filed: Myriad Genetics, Inc. has filed its Form 10-Q for the quarter ended June 30, 2026.
- Nasdaq Global Select Market: The company’s common stock (symbol: MYGN) continues to trade on the Nasdaq Global Select Market.
- Filing Status: Myriad is classified as an “Accelerated filer” and confirms compliance with all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Financial Highlights
| June 30, 2026 | December 31, 2025 |
|---|---|
| Total Assets: \$638.9 million | Total Assets: \$706.6 million |
| Total Stockholders’ Equity: \$303.9 million | Total Stockholders’ Equity: \$368.0 million |
| Common Stock Outstanding: 95.6 million shares | Common Stock Outstanding: 93.5 million shares |
Income Statement Highlights
- Net Loss (Q2 2026): \$43.2 million
- Net Loss (Six Months Ended June 30, 2026): \$77.3 million
- Net Loss (Q2 2025): \$330.5 million
- Net Loss (Six Months Ended June 30, 2025): \$330.6 million
- Basic and Diluted Net Loss Per Share (Q2 2026): \$0.46
- Basic and Diluted Net Loss Per Share (Q2 2025): \$3.57
Cash Flow and Shareholder Equity Movements
- Stock-Based Compensation: Continued expenses for stock-based compensation, with \$10.7 million recognized for six months ended June 30, 2026. Share issuance under compensation plans resulted in a net deduction of \$2.9 million for withholding tax.
- Accumulated Deficit: Significant accumulated deficit of \$1,122.7 million as of June 30, 2026, reflecting ongoing losses.
- Changes in Shareholder Equity: Shareholder equity decreased from \$368.0 million at year-end 2025 to \$303.9 million at June 30, 2026, driven by net losses.
Price-Sensitive Information & Investor Considerations
- Sustained Losses: Myriad Genetics, Inc. continues to post significant quarterly and year-to-date losses, but the net loss is substantially lower than the same period in 2025 (\$43.2 million vs. \$330.5 million for Q2). This may indicate improving cost controls or a reduction in extraordinary expenses, which could be viewed positively by investors if the trend persists.
- Decreasing Assets and Shareholder Equity: The company’s total assets and stockholder equity have declined since year-end 2025, which may raise concerns about liquidity and financial stability, particularly if losses continue.
- Stock-Based Compensation: Continued stock-based compensation expenses and share issuance for employee plans may dilute existing shareholder value.
- Accumulated Deficit: The company’s accumulated deficit remains high, underscoring the need for a turnaround in profitability.
- Share Count Increase: Common shares outstanding increased by 2.1 million, potentially diluting per-share metrics and impacting valuation.
- Compliance and Market Status: The company is not a shell company, remains compliant with SEC reporting, and maintains its Nasdaq Global Select Market listing, supporting investor confidence in corporate governance.
Potential Share Price Impact
- Positive: The reduction in quarterly net loss versus prior year suggests operational improvements. If investors perceive this as the start of a turnaround, it could support the share price.
- Negative: Decreasing assets and equity, ongoing losses, high accumulated deficit, and dilution from stock-based compensation may pressure the share price unless a clear path to profitability is communicated.
- Neutral-to-Mixed: The report contains both positive signals (losses shrinking) and negative signals (balance sheet deterioration), so share price movement will depend on investor interpretation, management guidance, and future outlook.
Disclaimer
This article is based on Myriad Genetics, Inc.’s Form 10-Q for the quarter ended June 30, 2026. It is intended for informational purposes only and should not be considered investment advice. Investors are encouraged to review the full SEC filing and consult with financial advisors before making investment decisions. The information herein is subject to change and may not reflect subsequent events or updated company guidance.
